Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sotevtamab - Alethia BioTherapeutics/International Biotechnology Center Generium

Next Previous
Drug Profile

Sotevtamab - Alethia BioTherapeutics/International Biotechnology Center Generium

Alternative Names: 16B5; AB-16B5; AB-sCLU mAB; Anti-clusterin monoclonal antibody - Alethia Biotherapeutics

Latest Information Update: 14 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Research Council Biotechnology Research Institute
  • Developer Alethia BioTherapeutics
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Clusterin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Non-small cell lung cancer
  • No development reported Solid tumours

Most Recent Events

  • 15 Feb 2024 Phase-II clinical trials in Colorectal cancer (Combination therapy, Metastatic disease, Neoadjuvant therapy, Late-stage disease) in Canada (IV) (NCT06225843)
  • 26 Jan 2024 Alethia Biotherapeutics plans a phase II trial for Colorectal Cancer (Combination therapy, Late-stage disease, Metastatic disease, Neoadjuvant therapy) in Canada (IV, Infusion) in February 2024 (NCT06225843)
  • 31 Dec 2023 Alethia Biotherapeutics completes a phase II trial in Non-small cell lung cancer (Metastatic disease, Late-stage disease, Combination therapy, Second-line therapy or greater) in Canada and the US (IV, Infusion) (NCT04364620)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top